Skip to main content
. 2022 Jun 25;8:83. doi: 10.1186/s40798-022-00469-0

Table 2.

Biological markers according to COVID status

Biomarkers1 F-NLR Rugby players, n = 779 Student athletes, n = 171
CRP, mg/L
COVID(−)Athletes, median (Q1; Q3), D0 1.1 (0.9; 4.0) 0.6 (0.3; 1.5)
     Athletes with levels > 5 mg/L, n % 47 (9.0) 9 (6.3)
 Among COVID(+)incident Athletes with paired pre-and post-infection samples, n = 161:
      Pre-COVID time point, median (Q1; Q3) 1.5 (1.0; 4.0) NA
     Athletes with levels > 5 mg/L, n % 9 (5.6) NA
      Post-COVID time point median (Q1; Q3) 2.0 (1.0; 4.0) NA
     Athletes with levels > 5 mg/L, n % 14 (8.7) NA
 Troponin, ng/L
 COVID (−)Athletes, median (Q1; Q3), D0 5.7 (3.8; 10.0) NA
     Athletes with levels > 34 ng/L, n % 11 (2.1) NA
 Among COVID(+)incident Athletes with paired pre-and post-infection samples, n = 136:
      Pre-COVID time point, median (Q1; Q3) 5.1 (4.1; 10.5) NA
     Athletes with levels > 34 ng/L, n % 8 (5.9) NA
      Post-COVID time point, median (Q1; Q3) 5.1 (4.7; 13.0) NA
     Athletes with levels > 34 ng/L, n % 8 (5.9) NA
 D-Dimer, ng/mL
 COVID(−)Athletes, median (Q1; Q3), D0 270.0 (215.0; 285.0) NA
     Athletes with levels > 400 ng/ml, n % 43 (8.3) NA
 Among COVID(+)incident Athletes with paired pre-and post-infection samples, n = 139
      Pre-COVID time point, median (Q1; Q3) 231.0 (215.0; 270.0) NA
     Athletes with levels > 400 ng/ml, n % 11 (7.9) NA
      Post-COVID(+) time point, median (Q1; Q3) 270.0 (215.0; 318.0) NA
     Athletes with levels > 400 ng/ml, n % 24 (17.3) NA

1Threshold for normal values was < 5 mg/L; < 34 ng/ml, and < 400 ng/mL for CRP, troponin I and D-Dimers, respectively. COVID(−) athletes: inclusion (D0) values described for those never having any evidence of prevalent or incident infection during the study (i.e., excluding also pre-infection values of later COVID(+)incident). For the COVID(+)incident players subgroup with laboratory assessments available pre- and post-SARS-CoV2 infection, median (Q1; Q3) days after infection was 7 (7; 12)